Fox Run Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Fox Run Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-37,136	Closed	-$717K	–	1237
2026 Q1	$717K	Buy	+37,136	New	+$836K	0.13%	285
2025 Q4	–	Sell	-23,759	Closed	-$715K	–	1194
2025 Q3	$715K	Buy	23,759 +7,070	+42%	+$212K	0.11%	346
2025 Q2	$607K	Buy	+16,689	New	+$602K	0.1%	387
2023 Q3	–	Sell	-4,887	Closed	-$225K	–	941
2023 Q2	$225K	Buy	+4,887	New	+$227K	0.06%	543
2022 Q4	–	Sell	-13,355	Closed	-$553K	–	840
2022 Q3	$553K	Buy	+13,355	New	+$686K	0.22%	139
2022 Q2	–	Sell	-5,392	Closed	-$392K	–	711
2022 Q1	$392K	Buy	+5,392	New	+$375K	0.22%	166
2021 Q3	–	Sell	-5,364	Closed	-$511K	–	591
2021 Q2	$511K	Buy	+5,364	New	+$559K	0.46%	40
2019 Q3	–	Sell	-3,214	Closed	-$204K	–	524
2019 Q2	$204K	Buy	+3,214	New	+$205K	0.14%	368
2018 Q1	–	Sell	-11,453	Closed	-$531K	–	885
2017 Q4	$531K	Buy	11,453 +7,453	+186%	+$365K	0.16%	266
2017 Q3	$213K	Buy	+4,000	New	+$237K	0.06%	589
2016 Q1	–	Sell	-2,600	Closed	-$292K	–	528
2015 Q4	$292K	Buy	+2,600	New	+$260K	0.23%	170

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Fox Run Management's RARE Position: Q2 2026 in Review

Fox Run Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 37,136 shares — an estimated $717K sold.

Fox Run Management first reported a position in RARE in Q4 2015 and held it in 11 quarters. The position peaked at $717K in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Fox Run Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 37,136 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $717K.
Fox Run Management first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and held it in 11 quarters.
Fox Run Management's Ultragenyx Pharmaceutical position peaked at $717K in Q1 2026.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.